The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 772K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

10 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
262
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI
Johnson & Johnson Pharmaceutical Research & Development
14
Structure-activity relationships for substrate-based inhibitors of human complement factor B.EBI
The University of Queensland
1
Profiling the enzymatic properties and inhibition of human complement factor B.EBI
University of Queensland
38
Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated DiseasesEBI
Novartis Institutes For Biomedical Research
39
Chemical Approaches to Modulating Complement-Mediated Diseases.EBI
The University of Queensland
34
Quinazoline and indole compounds to treat medical disordersBDB
Achillion Pharmaceuticals
89
Piperidinyl-indole derivatives complement factor B inhibitors and uses thereofBDB
Novartis
17
2-benzyl-benzimidazole complement factor B inhibitors and uses thereofBDB
Novartis
21
Complement factor B inhibitors and uses there ofBDB
Novartis
98
Piperidinyl-indole derivatives complement factor B inhibitors and uses thereofBDB
Novartis